Current Oncology Reports最新文献

{"title":"Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer.","authors":"Mohamed Ibrahim Elewaily, Akash Maniam, Alison Tree, Giuseppe Luigi Banna","doi":"10.1007/s11912-025-01665-3","DOIUrl":"https://doi.org/10.1007/s11912-025-01665-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>The introduction of PSMA-PET/CT scans is expected to increase the incidence of clinically lymph node-positive metastatic hormone-sensitive prostate cancer (mHSPC). The 8th AJCC-TNM classify disease with metastasis limited to pelvic nodes (cN1M0) and nonregional lymph nodes (M1a) as stage IV. To date, there is limited prospective evidence for management of this subgroup. Additionally, no specific recommendations currently exist for managing M1a as a distinct condition but as a part of CHAARTED low volume disease (LVD). Our review examines relevant results from phase III trials examining the management of clinically positive nodal disease over the last decade.</p><p><strong>Recent findings: </strong>STAMPEDE is the only phase III trial that gave recent data about cN1M0 and isolated M1a management. Cohort sub-analysis of the control arm showed improved failure-free survival after local radiotherapy (RT) plus Androgen Deprivation Therapy (ADT), while metastasis-free survival benefit from Abiraterone Acetate with Prednisolone (AAP) addition was noted when compared to standard of care (SOC), awaiting the overall survival (OS) benefit result. The STAMPEDE H arm showed a marginal significance of M1a stratified OS after RT. Future trials, including PEARLS, ALADDIN and STAMPEDE2, are expected to offer more insights. Interventional Phase III trials directed to clinically node positive patients are still needed to aid deciding on the best management, and nodal metastasis number and size impact on prognosis.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review.","authors":"Koku Sisay Tamirat, Michael James Leach, Nathan Papa, Jeremy Millar, Eli Ristevski","doi":"10.1007/s11912-025-01660-8","DOIUrl":"https://doi.org/10.1007/s11912-025-01660-8","url":null,"abstract":"<p><strong>Introduction: </strong>Men from culturally and linguistically diverse (CALD) backgrounds face challenges in accessing equitable and quality healthcare. However, little is known about the patterns of care among men diagnosed with prostate cancer (PCa) from CALD backgrounds. We aimed to map the available literature on patterns of care and treatment outcomes in men from CALD backgrounds who have PCa.</p><p><strong>Methods: </strong>We used the Johanna Briggs Institute scoping review methodology. We searched five bibliographic databases (Ovid MEDLINE, EMBASE, SCOPUS, CINAHL, and Ovid Emcare) and grey literature. We explored patterns of PCa care extending from screening and early detection to end-of-life care and treatment outcomes.</p><p><strong>Results: </strong>A total of 7,148 records were identified; 58 studies were included. Most studies were from the United States (US) (n = 41) and used ethnic origin (n = 14), nativity (n = 10), immigration history (n = 11), or country of birth (n = 13) as indicators of CALD. Most studies focused on screening and early detection for PCa (n = 37), specifically prostate-specific antigen (PSA) testing. Twelve papers were on PCa treatment (e.g., surgery, radiation therapy, and active surveillance), five on follow-up and supportive care, and four on treatment outcomes (i.e., change in measured PSA and PCa cancer-specific survival). There were disparities in the PCa care continuum and treatment outcomes between CALD and non-CALD patients. Factors influencing screening and early detection for PCa were systematically summarised and most addressed individual-level determinants.</p><p><strong>Conclusions: </strong>Key findings from our scoping review emphasised the existence of guideline-discordant care, disparities in PCa screening test use, and differences in PCa treatment received among men from CALD backgrounds. However, little is known about patterns of care in diagnostic modalities, treatment phases, and palliative and end-of-life care.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.","authors":"Kilian Trin, Cynthia Dalleau, Simone Mathoulin-Pelissier, Christophe Le Tourneau, Derek Dinart, Carine Bellera","doi":"10.1007/s11912-025-01667-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01667-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>The growth modulation index (GMI) is defined as the ratio between the time to progression of a new line of treatment and the previous line. This ratio can be used to determine whether the new line of treatment brings a clinical benefit. It has been proposed as an outcome in trials evaluating non-cytotoxic drugs. Its interest lies in the intra-patient comparison. The terminology employed to refer to the GMI, as well as its definitions, are highly variable in the literature. Some uses of the GMI are arbitrary and not based on any scientific rationale. Our aim is to describe how the GMI is reported in the scientific literature.</p><p><strong>Recent findings: </strong>We carried out a scoping review using PubMed, Scopus, Web of Science and BASE (Bielefeld Academic Search Engine). The algorithm was composed of the terms \"growth modulation index\", \"time to progression ratio\" and \"progression-free survival ratio\". Documents in English, with full-text available, published up to 2023, were included. Among 227 included documents, 166 of which discussed GMI specifically. On these 166 documents, 76 reported on observational studies, 62 on interventional studies and 17 on methodological or statistical developments pertaining to the GMI. All were about oncology. Our review highlights significant variability in the reporting and use of the GMI. To address this, we propose standardized reporting guidelines. Additionally, we emphasize the need for methodological and statistical developments to improve the use of the GMI and to develop novel GMI-based trial designs.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Glioma Management: The Pivotal Role of Surgical Neuro-Oncology in Driving Innovation and Translational Research.","authors":"Jack M Shireman, Simon G Ammanuel, Mahua Dey","doi":"10.1007/s11912-025-01662-6","DOIUrl":"https://doi.org/10.1007/s11912-025-01662-6","url":null,"abstract":"<p><strong>Purpose of the review: </strong>This study aims to assess the evolution of the role of surgery in advancing the treatment paradigm of primary central nervous system malignancies, gliomas.</p><p><strong>Recent findings: </strong>Diagnostic and therapeutic surgical intervention is the cornerstone for management of all gliomas. Current treatment guidelines for all gliomas include maximal safe resection, with concurrent and adjuvant chemo/radiotherapy, or other targeted molecular therapies, for high-grade gliomas and subsets of low-grade gliomas dependent on mutation profiling and IDH status. The extent of surgical resection affects overall survival across all grades of gliomas. Recently, several technological advances have augmented a surgeon's ability to push the boundaries of extent of resection, while also opening the door for novel intraoperative diagnostic and therapeutic interventions. Increasingly surgery is playing a pivotal role in the management of gliomas from diagnosis to therapeutic intervention, to drug delivery and progression monitoring. Novel technological advances such as advanced image guidance, fluorescence markers, intraoperative functional mapping, histological identification, and intraoperative radiation and drug delivery, provide a fertile ground for combining innovative modalities together to drive better treatment strategies and outcomes for patients.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients.","authors":"Adam G Fish, David C Madoff","doi":"10.1007/s11912-025-01663-5","DOIUrl":"https://doi.org/10.1007/s11912-025-01663-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Malignancy-related hemorrhage is a complex and potentially life-threatening complication that requires a multidisciplinary approach. This review examines the role of endovascular interventions in achieving hemostasis when conservative measures fail, focusing on their indications, efficacy, and associated risks.</p><p><strong>Recent findings: </strong>Endovascular therapies have demonstrated high success rates in controlling hemorrhage from various malignancies. Bronchial artery embolization (BAE) effectively manages hemoptysis in lung cancer, though recurrence remains a challenge. Gastrointestinal tumor bleeding can be treated with targeted embolization, but ischemic complications require careful technique. Hematuria due to urinary and prostate malignancies responds well to superselective embolization, and uterine artery embolization (UAE) is a viable option for gynecologic malignancy-related bleeding. Emerging techniques, such as bronchial artery chemoembolization, show promise in improving long-term control. Endovascular interventions are a cornerstone in the management of malignancy-related hemorrhage, offering minimally invasive and effective hemostatic solutions. While recurrence and complications remain a concern, advancements in embolization techniques and materials continue to improve outcomes. A multidisciplinary approach is essential to optimizing patient care.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young People with Cancer: A Growing Population in Need of United Attention.","authors":"Lindsay F Schwartz, Sarah P Shubeck, Elizabeth C Danielson","doi":"10.1007/s11912-025-01661-7","DOIUrl":"https://doi.org/10.1007/s11912-025-01661-7","url":null,"abstract":"<p><p>Each year, over 84,000 young people in the United States are diagnosed with cancer. These patients face unique burdens that defy historical \"adolescent and young adult\" and \"early-onset cancer\" silos. These groups share common vulnerabilities, including financial toxicity, disruptions to education and career development, and inadequate survivorship care. Research efforts to address these shared challenges remain inefficient due to parallel and uncoordinated investigations. Health policy decisions are similarly impacted, with the lack of a unified framework potentially leading to gaps in insurance coverage, disparities in resource allocation, and incomplete data collection on young people diagnosed with cancer. To address these challenges, a collaborative and integrated strategy across clinical care, research, and health policy is urgently needed. By unifying efforts and recognizing the shared experiences of young people with cancer, we can develop more effective support systems, optimize outcomes, and reduce the long-term burden of cancer for this fast-growing and vulnerable population.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"History of Leukemia, Revisited.","authors":"Carlos Ortiz-Hidalgo","doi":"10.1007/s11912-025-01658-2","DOIUrl":"https://doi.org/10.1007/s11912-025-01658-2","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Provide a general historical overview of leukemia, emphasizing the early discoveries that led to its characterization.</p><p><strong>Recent findings: </strong>Leukemia recognition began in the late 19th century with the advent of the microscope. Leeuwenhoek and Swammerdam described erythrocytes, while Lieutaud first observed globuli albicantes, later identified as lymphocytes by Hewson. Early case studies by Velpeau, Donné, Bennett, Craigie, Virchow, and Fuller suggested that leukocytosis could occur without infection. Virchow coined the term \"leukemia,\" while Bennett proposed \"leucocythemia.\" Neumann identified the bone marrow as the source of blood cells and leukemia, coining the term \"myelogenous leukemia,\" and Ehrlich classified leukemia into myeloid and lymphoid types. In 1914, Boveri linked chromosomal abnormalities to cancer, and in 1960, Nowell and Hungerford discovered the Philadelphia chromosome. The use of mustard gas in WWI led to the development of chemotherapy drugs like chlorambucil and busulfan. The Human Genome Project further advanced leukemia diagnosis and treatment. Leukemia, like many diseases, has evolved due to changes in causative factors such as viruses, bacteria, and genetic mutations, which have impacted its pathogenesis and treatment. It will undoubtedly continue to evolve, with new scientists working towards a cure for this devastating disease.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions, Knowledge, and Attitudes of General Population About Prostate Cancer-Associated Risk Factors: A Systematic Review of Qualitative Studies Focusing on Lifestyle.","authors":"Catarina Leitão, Vanessa Neto, Luanna Silva, Marta Estrela, Margarida Fardilha, Fátima Roque, Maria Teresa Herdeiro","doi":"10.1007/s11912-025-01653-7","DOIUrl":"https://doi.org/10.1007/s11912-025-01653-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Prostate cancer (PCa) is the most prevalent cancer and the third deadliest in Europe among men. PCa has several well-established risk factors; however, the influence of lifestyle factors remains under investigation, which may hinder efforts to encourage healthier behavior adoption. Thus, this systematic review explored the general population's perceptions, knowledge, and attitudes regarding PCa-related risk factors.</p><p><strong>Recent findings: </strong>Eighteen qualitative studies were included after searching PubMed, Scopus, Web of Science, and EMBASE scientific databases between January 2013 and February 2023. Five major themes emerged from the 18 included studies: PCa knowledge, risk factors, lifestyle pattern changes, motivation/barriers to changing habits, and lifestyle advice support. Participants identified age, family history, genetics, and race/ethnicity as risk factors for PCa, but no consensus has been reached regarding lifestyle. However, most of the participants were willing to adopt healthier habits. Support from healthcare professionals (HPs), family, and friends, the desire for more time with loved ones, and fear of PCa consequences were cited as motivators for habit changes. However, poor economic conditions, work schedules, age, and PCa limitations hamper lifestyle changes. Effective interventions require personalized support and credible information from healthcare providers. Collaboration between family, friends, and HPs is crucial for promoting healthier behaviors and enhancing PCa management. This systematic review highlights the need for further research and innovative approaches to empower individuals towards healthier lifestyles, which could help prevent PCa or, at the very least, promote better treatment outcomes.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Clinical PET Tracers in the Pipeline for Melanoma.","authors":"Nora Jaber, Hanna Saadani, Winnie Schats, Else A Aalbersberg, Marcel P M Stokkel","doi":"10.1007/s11912-025-01659-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01659-1","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this review is to provide an overview of novel clinical PET tracers in the pipeline for melanoma. Secondarily, to provide a head-to-head comparison with the current clinical standard used in clinical practice, [¹⁸F]FDG, if available.</p><p><strong>Recent findings: </strong>[¹⁸F]FDG PET/CT has become important in the clinical setting for melanoma as it serves many purposes, but lacks other important qualities due its nonspecific nature. There is an increased clinical need for specific tracers. Many new PET tracers, such as melanin-targeted and antibody-based probes, have been studied in melanoma with the intention of achieving high sensitivity detection of metastases and small lesions. There are four main groups of PET tracers in de pipeline for melanoma: melanin-, FAP-, PD-1/PD-L1- and CD8+ T cell-tracers. Melanin-targeted tracers and FAP inhibitors revealed potential for diagnostic application, whilst PD-1/PD-L1 and CD8+ T cell tracers demonstrated potential for response assessment and prediction. In conclusion, research has revealed promising results from current (ongoing) studies; however, more melanoma patients need to be included to further assess the value of these tracers.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.","authors":"Salma Elmenawi, Mohamed Fawzy","doi":"10.1007/s11912-025-01650-w","DOIUrl":"https://doi.org/10.1007/s11912-025-01650-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review provides a comprehensive understanding of the ALK gene, encompassing its prevalence, genetic alterations, and significance in neuroblastoma diagnosis, outcome prediction, and targeted therapy utilization. The insights presented aim to inform future research directions and clinical practices in this field.</p><p><strong>Recent findings: </strong>High risk neuroblastoma, comprising approximately 50% of all cases, presents a particularly poor prognosis. In 2008, the discovery of ALK aberrations in neuroblastoma marked a significant breakthrough, leading to the recognition of ALK as a target for tumors with activating ALK alterations. This discovery has paved the way for the development of various ALK inhibitors, which have shown promising clinical efficacy. ALK amplification, often observed alongside MYCN amplification, has been associated with unfavorable outcomes in patients. Activating mutations in the kinase domain of ALK, particularly at hotspot positions F1174, R1275, and F1245, have been identified. These mutations can occur at clonal or subclonal levels, posing challenges for early detection and potentially influencing disease progression and therapy resistance. The availability of ALK inhibitors, initially developed for adult cancers, has expedited the translation of this knowledge into targeted therapies for neuroblastoma. However, resistance to ALK inhibitors can emerge as a result of treatment or preexist as subclones within the tumor prior to therapy. Future trials should focus on identifying additional targets complementing ALK inhibition to enhance treatment efficacy and overcome acquired resistance. Furthermore, the utilization of circulating tumor DNA as a non-invasive approach for longitudinal monitoring of ALK-positive neuroblastoma patients, in combination with radiographic evaluation of treatment response, holds promise for understanding dynamic tumor changes over time.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}